PHARMA PACKAGING
Mold-Tek Packaging shares surge 17% as Q2 FY 27 profit jumps 35% YoY to Rs 21 crore
Mold-Tek Packaging shares surged nearly 17% after the company reported a 35.5% YoY rise in Q2 FY27 net profit and 30.5% revenue growth. Strong pharma and FMCG packaging volumes supported performance, while new product launches and expansion plans strengthened its growth outlook.
Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: Report
Indian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision followed the discovery of failures in the company's quality management system. A joint inspection cited lapses that affected drug safety and quality, leading to a recall of several eye-drop brands. Significant adverse cases have raised concerns regarding product contamination, prompting further investigation.
These large-, mid- and small-cap stocks can give more than 20% return in 1 year, according to analysts
Here’s one thing that is worth clarifying, because it is in the headlines. Large global technology companies have been announcing heavy spending on AI, and there has been some correction in those stocks because of it. It is natural to worry that this will spill over into the Indian market. It most likely will not.
PM Modi reviews projects worth over Rs 16,000 crore across 31 States, UTs at 54th PRAGATI meeting
Prime Minister Narendra Modi chaired the 54th PRAGATI meeting to evaluate infrastructure projects worth over Rs 16,000 crore. The meeting focused on enhancing railway station redevelopment and boosting local pharmaceutical manufacturing. PM Modi emphasized the importance of timely execution of projects and inter-agency coordination. He also highlighted the need for supporting local artisans through Ekta Malls and maintaining close monitoring on these initiatives.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
When a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling used cars reported numbers that fell short, and the street punished the stock severely. But it is not just the clear misses. Anything that is well-owned and presents disappointing numbers is seeing double-digit cuts.
India to remain top of the Asian pie for Advent
Advent International has successfully raised $30 billion for its global buyout and mid-market funds. The firm plans to invest significantly in India, expecting healthy GDP growth in the country. With recent investments including Yatharth Hospitals and Aditya Birla Housing Finance, Advent remains confident in the Indian market potential. The new fund is set to target various sectors including healthcare, technology services, and industrials.
- Go To Page 1
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
At this juncture, what companies say about their Q2 results, and their outlook for Q3 and Q4, matters a great deal – but only to a certain extent. A company can plan only for what is in its control. No management can predict what the US President will decide, or which way the trouble in the Gulf will turn next.
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.
FMCG stocks lost their tag of defensive stocks, will they get it back? 7 FMCG stocks with an upside potential of up to 32%
Those who have been following the market for long know this: When there is nervousness on the street, money instinctively moves towards a particular sector. That is the one with companies that sell soaps, biscuits, tea – all the everyday things that people buy whether the news is good or bad. Yes, we are talking about the FMCG sector.
No love for the middle: CPHI Milan exposes India’s pharma scaling challenge
Indian pharma and chemical companies at CPHI Milan say the China+1 opportunity is real, but a “missing middle” in the MSME ecosystem, marked by financing gaps, limited scale and technology constraints, is holding back export growth.
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%
A piece of advice for those who still have the stomach to invest in the current volatile market. Don’t take any price action as the gospel truth; look beyond the index movements. And, finally, be both cautious and selective in your stock picks.
Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullish
Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing medicine prices by 70%. Jefferies and Emkay expect manageable earnings impacts, despite near-term margin pressures. Jefferies favours Fortis, Manipal, Apollo, Max Healthcare and Medanta, citing strong demand and attractive valuations.
Healthcare paradox: More access, but who pays?
Scaling too fast is irrelevant. The real problem is that India still confuses more hospitals, more doctors and more medicines with better healthcare.
GST Council meeting 2026: What may change as GST 2.0 takes aim at ITC, refunds, arrest powers and other reforms
GST Council Meeting 2026: The GST Council, meeting in New Delhi, is expected to propose significant reforms for tax administration. One reform will address arrest powers for tax officers, requiring court orders for detentions. Input tax credits on certain business expenses may also be unblocked, which could benefit various industries. Small taxpayers may see a simplified registration process and reduced compliance requirements.
Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims
Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.
Nifty valuations near post-Covid lows. Alchemy Capital’s Alok Agarwal explains what investors should buy now
Nifty valuations have reset sharply from 2024 levels and are now near post-Covid lows, says Alchemy Capital’s Alok Agarwal. He sees the next phase of market growth broadening beyond large caps. Mid- and small-caps, AI infrastructure, healthcare, manufacturing and select defence companies offer opportunities, while global yields and FPI flows remain key.
Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?
Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies.
New indicator for New India: 25 stocks whose numbers can reveal what is in store for the economy and the stock market
For decades, there was a familiar way to understand the Indian consumer. Economists waited for GDP, industrial production, inflation, credit growth and other official numbers, and then used them to work out whether households were spending more or pulling back. Those indicators still matter. But the Indian consumer has changed faster than the dashboard used to track consumption and spending patterns. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
94% of packaged foods may face warnings under nutrient limits; FSSAI ex-chief Pawan Kumar Agarwal urges SC for phased food warning rollout
Former FSSAI chief Pawan Kumar Agarwal has urged the Supreme Court to consider a phased rollout of front-of-pack food warnings, warning that the proposed nutrient thresholds could place labels on more than 94% of packaged foods and dilute their impact. His foundation suggested interim thresholds followed by stricter limits over three to five years, with mandatory labelling proposed from July 1, 2027.
Thinking long term and enduring volatility is the only way out: 5 mid-caps from different sectors with upside potential of up to 24%
If you are an investor with some skin in the game, be ready to see some underperformance. Why? Because valuation readjustment can take more time in a volatile market. Buying a good business in a correction does not mean its price stops falling the day you buy. It can drift lower, or go nowhere, for a while, as the market takes its time to settle. That is the nature of a volatile phase, and why it is an exercise in patience.
Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal
The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology partnerships and joint ventures. India aims to become a global hub for medical innovation and device development. Hospitals must offer transparent treatment packages and ethical patient care practices. Enhancing interpreter services will improve foreign patient confidence and communication.
Munde’s action wins public praise, but court rebukes FDA over process
FDA Commissioner Tukaram Mundhe faces criticism after initial praise for regulatory actions. The Bombay High Court has repeatedly pulled up the FDA for overreach and procedural lapses. The regulator faced setbacks with licence cancellations and fines for minor compliance issues. The state government also intervened after traders petitioned against a ban on loose edible oil. This situation highlights challenges faced by the food and drugs regulator in its enforcement activities.
Stocks in news: Bharti Airtel, Happiest Minds Technologies, PVR INOX, Milky Mist Dairy and Mankind Pharma
Indian equity markets ended lower on August 31, responding to prevailing global economic dynamics. A modest decline in the Nifty50 index brought it below essential moving averages. Key corporate updates emerged, including major merger announcements and buyback initiatives from Happiest Minds Technologies and PVR INOX. Milky Mist Dairy showed remarkable profit growth, whereas E2E Networks secured a vital contract.
Tukaram Mundhe cracks down: Maharashtra FDA cancels licence of Cipla's Pune unit over regulatory violations, Cipla contests action
Maharashtra FDA cancelled Cipla's Pune C&F unit drug sale licenses due to serious storage and recall issues. Inspectors found unauthorized claims on Reactin Plus Tablets packaging and seized stock valued at over eleven lakh rupees. The company failed to fully comply with market recall directions and address further distribution system discrepancies. Cipla Pharma & Life Sciences is contesting the order, stating the matter is currently sub judice.
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindo’s inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.
Cipla Pharma license cancellation: FDA withdraws order after HC raps it for going 'overboard'
Maharashtra FDA withdrew its order to cancel Cipla Pharma's drug sale license after court intervention. The Bombay High Court criticized the regulator for acting in a high-handed and overboard manner. The FDA will now issue a fresh show cause notice to the company for a reasoned order. This action followed alleged irregularities in packaging, storage, and recall of specific tablets.
Mold-Tek Packaging board approves 1:1 bonus issue, Rs 3 final dividend
Mold-Tek Packaging’s board has approved a 1:1 bonus issue and recommended a final dividend of Rs 3 per share for FY26. Under the proposal, shareholders will receive one bonus share of Rs 5 face value for every share held. The company will announce the record date later, while the dividend will be declared at its annual general meeting.
Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark
A Delhi court has permanently stopped Sainus Pharmaceutical Private Limited from using the 'Udaan' trademark. This ruling came after RSPL Health Private Limited filed a case alleging trademark infringement. RSPL Health, known for its 'Ghari' detergent brand, had registered its 'Udan' mark earlier. The court found Sainus Pharma's mark to be identical and deceptively similar to RSPL's registered trademark.
Panel to evaluate safety of plastic bottles for drugs
The government is constituting an expert panel to examine if plastic and PET bottles used for packaging pharma products are safe.
Load More
